甘李药业
(603087)
| 流通市值：222.63亿 | | | 总市值：249.07亿 |
| 流通股本：5.31亿 | | | 总股本：5.94亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,905,670,877.67 | 1,229,765,113.65 | 557,999,537.96 | 1,712,270,496.85 |
| 营业收入 | 1,905,670,877.67 | 1,229,765,113.65 | 557,999,537.96 | 1,712,270,496.85 |
| 二、营业总成本 | 1,645,843,381.45 | 1,108,907,254.24 | 528,077,591.01 | 2,228,869,369.17 |
| 营业成本 | 481,189,719.14 | 322,655,986.2 | 150,830,624.26 | 405,803,824.65 |
| 税金及附加 | 17,933,843.14 | 12,493,109.55 | 6,061,051.09 | 20,954,253.84 |
| 销售费用 | 703,633,555.05 | 465,243,177.81 | 224,729,850.74 | 1,086,546,460.67 |
| 管理费用 | 141,626,147.56 | 100,695,377.33 | 46,800,804.48 | 247,389,398.2 |
| 研发费用 | 369,945,734.16 | 261,962,985.39 | 119,936,250.47 | 562,469,155.04 |
| 财务费用 | -68,485,617.6 | -54,143,382.04 | -20,280,990.03 | -94,293,723.23 |
| 加:公允价值变动收益 | -17,576,525.82 | 9,902,075.97 | 17,706,102.62 | -80,655,151.19 |
| 加:投资收益 | 59,839,944.9 | 21,034,510.73 | 1,578,563.69 | 87,566,857.88 |
| 资产处置收益 | 45,822.47 | 45,822.47 | 140,716.06 | 485,848.9 |
| 资产减值损失(新) | -3,352,763.4 | -4,326,667.96 | - | -79,043,365.13 |
| 信用减值损失(新) | 4,492,847.21 | 5,476,246.03 | 5,183,449.3 | -27,246,137.3 |
| 其他收益 | 13,936,831.47 | 11,053,501.82 | 5,295,268.14 | 46,618,045.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 317,213,653.05 | 164,043,348.47 | 59,826,046.76 | -568,872,773.96 |
| 加:营业外收入 | 2,931,333.37 | 2,185,720.84 | 72,251.09 | 2,942,387.32 |
| 减:营业外支出 | 9,123,853.22 | 6,535,466.78 | 2,207,715.29 | 16,542,568.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 311,021,133.2 | 159,693,602.53 | 57,690,582.56 | -582,472,954.8 |
| 减:所得税费用 | 44,545,285.75 | 25,538,397.62 | 8,467,364.65 | -142,956,574.44 |
| 六、净利润 | 266,475,847.45 | 134,155,204.91 | 49,223,217.91 | -439,516,380.36 |
| 持续经营净利润 | 266,475,847.45 | 134,155,204.91 | 49,223,217.91 | -439,516,380.36 |
| 归属于母公司股东的净利润 | 266,475,880.66 | 134,155,242.69 | 49,223,261.29 | -439,516,357.48 |
| 少数股东损益 | -33.21 | -37.78 | -43.38 | -22.88 |
| (一)基本每股收益 | 0.47 | 0.24 | 0.09 | -0.78 |
| (二)稀释每股收益 | 0.47 | 0.24 | 0.09 | -0.78 |
| 八、其他综合收益 | 869,456.92 | 1,789,558.67 | -1,122,921.13 | 6,882,165.06 |
| 归属于母公司股东的其他综合收益 | 869,456.92 | 1,789,558.67 | -1,122,921.13 | 6,882,165.06 |
| 九、综合收益总额 | 267,345,304.37 | 135,944,763.58 | 48,100,296.78 | -432,634,215.3 |
| 归属于母公司股东的综合收益总额 | 267,345,337.58 | 135,944,801.36 | 48,100,340.16 | -432,634,192.42 |
| 归属于少数股东的综合收益总额 | -33.21 | -37.78 | -43.38 | -22.88 |
| 公告日期 | 2023-10-31 | 2023-08-25 | 2023-04-28 | 2023-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |